Patients diagnosed with stage IIB disease on mammography, ultrasound, or breast MRI have lower rates of detection for unsuspected more-advanced disease and upstaging [18,19] and may therefore be considered for FDG PET/CT based on the Ki67 index and the molecular subtype of the tumor. This evidence concerns the gene MKI67 and neoplasm.